Alaunos Therapeutics, Inc. Revenue From Contract With Customer Excluding Assessed Tax

• Alaunos Therapeutics, Inc. showed a decrease of -50.0% in Revenue From Contract With Customer Excluding Assessed Tax from 2024 to 2025.
• This data is from Alaunos Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 31, 2026.
• XBRL data for this metric is available from 2016 to 2025 (9 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
• Over the full 9 years of available data (2016 to 2025), Alaunos Therapeutics, Inc.'s Revenue From Contract With Customer Excluding Assessed Tax has declined by 99.9%.
• Historical annual values: Fiscal year 2025: $5.0 thousand | Fiscal year 2024: $10.0 thousand | Fiscal year 2023: $5.0 thousand | Fiscal year 2022: $2.92 million | Fiscal year 2021: $398.0 thousand | Fiscal year 2020: $0.00 | Fiscal year 2018: $146.0 thousand | Fiscal year 2017: $6.39 million | Fiscal year 2016: $6.86 million.
• Data sourced from SEC EDGAR public filings as of June 23, 2026.

Last verified: June 23, 2026